Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DNCL002122

Drug Information
NameLDE225
SynonymsErismodegib
CompanyNovartis Pharmaceuticals
IndicationBasal cell cancer
[ICD9: 173   ICD10: C44]
Phase II    
Basal cell carcinoma (lead indication), solid tumors
[ICD9: 140-199, 173, 210-229   ICD10: C00-C75, C44, C7A, C7B, D10-D36, D3A]
Phase II    
CML
[ICD9: 205.1   ICD10: C92.1]
Phase I    
CML (combination therapy)
[ICD9: 205.1   ICD10: C92.1]
Phase I    
Neoadjuvant pancreatic cancer (see also leukemia, solid tumors, skin)
[ICD9: 140-199, 140-229, 157, 208.9, 210-229   ICD10: C00-C75, C00-C96, C25, C7A, C7B, C91-C95, D10-D36, D3A]
Phase I/II    
Solid tumors (adults and pediatric) (see also leukemia, pancreatic, skin)
[ICD9: 140-199, 208.9, 210-229   ICD10: C00-C75, C7A, C7B, C91-C95, D10-D36, D3A]
Phase I    
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C26H26F3N3O3/c1-16-14-32(15-17(2)34-16)24-12-9-20(13-30-24)31-
25(33)23-6-4-5-22(18(23)3)19-7-10-21(11-8-19)35-26(27,28)29/h4-13
,16-17H,14-15H2,1-3H3,(H,31,33)/t16-,17+
InChIKeyVZZJRYRQSPEMTK-CALCHBBNSA-N
Canonical SMILESCC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F    
Isomeric SMILESC[C@@H]1CN(C[C@@H](O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC
(F)(F)F
FormulaC26H26F3N3O3
PubChem Compound IDCID 24775005.
TargetHedgehog Signaling Pathway
Smoothened receptor



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543